Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Designer Protein to Prevent Prostate Cancer Cell Growth

Published: Friday, January 17, 2014
Last Updated: Friday, January 17, 2014
Bookmark and Share
Researchers are creating a "designer" protein that could be effective at treating prostate cancer when other therapies fail.

In laboratory tests, the protein hindered the growth of cancer cells even in conditions where conventional therapies are ineffective.

The researchers, from Imperial College London and the University of Essex, hope to develop the protein into a therapeutic that could be trialled in patients within five years.

The findings are published today in the journal Oncotarget.

Prostate cancer is the most common type of cancer in men. Around 37,000 UK men are diagnosed with the disease each year. Many prostate cancers develop very slowly, but in a small proportion of cases the cancer grows more quickly and spreads to other areas of the body, sometimes proving fatal.

Prostate cancers are only able to grow when they are exposed to male hormones such as testosterone. These hormones bring about their effects by binding to specific receptors. Many existing therapies target these receptors, yet after an average of two years the cancer becomes resistant to treatment. In this phase, hormones continue to drive the growth of cancer cells.

In this new study, the researchers have designed a new protein which blocks the hormone receptors and consequently stops prostate cancer cells from growing in the laboratory. The therapy was successful even in circumstances that lead to the failure of conventional treatments.

Dr Charlotte Bevan, senior author of the study, from the Department of Surgery and Cancer at Imperial College London said: "Eleven thousand men die from prostate cancer each year in the UK. Existing treatments are good at first but frequently fail after a couple of years. Once the cancer moves to the more aggressive stage, there are few therapies available.

"Our team is seeking to design a new therapy that will help patients once the other ones have failed. There is a lot of research supporting the idea that the androgen receptor continues to drive prostate cancer growth, so we have been investigating novel methods to block this pathway." 

The team is designing a novel therapy by combining two separate proteins to create a hybrid. One half binds to the receptor, whilst the other half blocks the receptor's activity. The research demonstrates that both of these factors are important in blocking activity, and consequently the growth of the cancer. 

"So far, the research has only been carried out in prostate cancer cells in the laboratory.  These proof of principle experiments are really promising, but more work is needed before these therapies are ready for clinical trials" said Dr Greg Brooke, first author of the study, now at the School of Biological Sciences, University of Essex. "The next step is to continue research in cell models to refine the therapy into something that is specific, potent and easy to deliver.

"It's exciting to think that this research could offer new hope for men with advanced prostate cancer."

This work was supported by Prostate Cancer UK (formerly Prostate Action), The Martin Harris Research Fellowship, Imperial Innovations and Johnson & Johnson Services Inc., an affiliate of Johnson & Johnson Innovation.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Switching Off Cancers' Ability to Spread
A key molecule in breast and lung cancer cells can help switch off the cancers' ability to spread around the body.
Tuesday, March 22, 2016
‘Simple Rules’ Calculate Ovarian Cancer Risk
Scientists have formulated a system that uses ultrasound images to accurately work out the likelihood of an ovarian growth being cancerous.
Wednesday, January 20, 2016
New Technique Negotiates Neuron Jungle To Target Source Of Parkinson’s Disease
Researchers from Imperial College London and Newcastle University believe they have found a potential new way to target cells of the brain affected by Parkinson’s disease.
Wednesday, September 23, 2015
New Drug Target Identified for Serious Heart and Lung Condition
A gene has been identified that sheds new light on a potentially fatal heart and lung condition and could lead to a new treatment.
Friday, August 14, 2015
Gene Therapy for Cystic Fibrosis Shows Encouraging Trial Results
A therapy that replaces the faulty gene responsible for cystic fibrosis in patients' lungs has produced encouraging results in a major UK trial.
Friday, July 03, 2015
Researchers Develop New Breath Test to Diagnose Oesophageal and Gastric Cancer
Test will now be tested in a larger trial involving three hospitals in London.
Tuesday, June 23, 2015
Imperial Researchers Win Health Foundation Grant for Cancer Innovation Study
Each project will receive over £450,000 of funding to support the research.
Tuesday, May 26, 2015
Engineering Bacteria for Vaccine Delivery
An eight million Euro project has been launched with the aim of engineering bacteria to deliver vaccines against antibiotic-resistant infections.
Monday, May 18, 2015
Diet Swap has Dramatic Effects on Colon Cancer Risk for Americans and Africans
New study confirms that a high fibre diet can substantially reduce risk.
Saturday, May 02, 2015
Protein That Boosts Immunity to Viruses and Cancer Discovered
Researchers now developing a gene therapy designed to boost the infection-fighting cells.
Saturday, April 18, 2015
New Test can Help Doctors Choose Best Treatment for Ovarian Cancer
ADNEX discriminate between benign and malignant tumours with a high level of accuracy.
Friday, October 17, 2014
New Cancer Drug To Begin Trials In Multiple Myeloma Patients
Scientists at Imperial College London have developed a new cancer drug which they plan to trial in multiple myeloma patients by the end of next year.
Tuesday, October 14, 2014
First Pictures of BRCA2 Protein Show How it Works to Repair DNA
Researchers purified the protein and used electron microscopy to reveal its structure.
Thursday, October 09, 2014
Protein ‘Map’ Could Lead to Potent New Cancer Drugs
Findings will help scientists to design drugs that could target NMT enzyme.
Saturday, September 27, 2014
What Lies Behind the Death of Stem Cells
Researchers have identified key processes that control stem cell survival, providing insights that could improve their use in medicine.
Friday, September 19, 2014
Scientific News
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Testing Nanoparticle Drug Delivery in Dogs
Scientists have tested a nanoparticle drug delivery against bone cancer in dogs with promising results.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Exploiting Malaria’s Achilles’ Heel
Researchers have uncovered an Achilles' heel in malaria's anti-drug treatment arsenal that could lead to a disease cure.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!